HotSpot Therapeutics Secures $65M
HotSpot Therapeutics Secures $65M Back to HomeBOSTON, MA, HotSpot Therapeutics has announced the completion of a $65 million Series B financing. HotSpot Therapeutics, a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting nature's regulatory sites, today announced the completion of a $65 million Series B financing. "We are thrilled to have the support of a top tier investor syndicate to realize our vision of designing and developing first-in-class allosteric medicines," said Jonathan Montagu, CEO and co-founder of HotSpot Therapeutics. HotSpot Therapeutics is creating a new paradigm for allosteric medicines that exploits natural control mechanisms. About HotSpot TherapeuticsHotSpot Therapeutics is targeting nature's regulatory mechanisms to create allosteric medicines that exhibit high precision and potency.